ESR1 and breast neoplasm: The derivation of a STAT3 pathway signature that predicts poor prognosis and resistance to endocrine therapy indicates that a subpopulation of ER+ breast tumors might be the rational targets for SFX-01 therapy in combination with current endocrine therapies.